Virus-Like-Vaccines against HIV

Virus-Like-Vaccines against HIV

Blog Article

Protection against chronic infections has necessitated the development of ever-more potent vaccination tools.HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system.Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses.Here, we review the emerging concept of merging these two technologies into virus-like-vaccines (VLVs) for the targeting of HIV.

Such vaccines are immunologically perceived as viruses, as they Ball - Batter - Helmet infect cells and produce VLPs in situ, but they only resemble viruses, as the replication defective vectors and VLPs cannot propagate an infection.The inherent safety of such a platform, despite robust particle production, is a distinct advantage over live-attenuated vaccines that must balance safety and immunogenicity.Previous studies have delivered VLVs encoded in modified Vaccinia Ankara vectors and we have developed the concept into a single-reading adenovirus-based technology capable of eliciting robust CD8+ and CD4+ T cells responses and trimer binding antibody responses.Such vaccines Football - Accessories offer the potential to display the naturally produced immunogen directly and induce an integrated humoral and cellular immune response.